http://rdf.ncbi.nlm.nih.gov/pubchem/patent/ES-2549077-T3
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_69ece09bafee7e0c49d1f7951a3faa2c |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-505 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/Y10T436-24 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/Y10S436-825 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2866 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-6848 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-6854 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-32 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12P21-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12P21-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-53 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-46 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-68 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-28 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-32 |
| filingDate | 2005-04-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2015-10-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_30f1ded85f5093ac92e38259e800ff8d http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f0915c970113a9c4138c0a6ecfb8c2f6 |
| publicationDate | 2015-10-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | ES-2549077-T3 |
| titleOfInvention | Mass spectrometry of antibody conjugates |
| abstract | A method of detecting antibody-drug conjugated compounds comprising: (i) processing by immunoaffinity membrane selection a biological sample that has been collected from a biological source in contact with a antibody-drug conjugate compound having Formula I previously : Ab- (LD) p I in which Ab is an antibody that binds to one or more antigens associated with tumors or cell surface receptors; D is a drug residue selected from a maitansinoid or auristatin; L is a linker covalently linked to Ab and covalently linked to D, wherein L is formed from a linker reagent selected from N-succinimidyl 4- (2-pyridylthio) propanoate (SPDP), succinimidyl-4- (N- maleimidomethyl) cyclohexane-1-carboxylate (SMCC) and N-succinimidyl-4- (2-pyridylthio) pentanoate (SPP), or L is selected from maleimidocaproyl (MC), maleimidopropanoyl (MP) and maleimidocaproyl-valine-citrulline-paraaminobenzyloxycarbonyl (benzyloxycarbonyl) MC-vc-PAB); and p is 1, 2, 3, 4, 5, 6, 7 or 8; wherein a test sample is formed by contacting the biological sample with an immunoaffinity membrane comprising an immobilized antigen and elution of the test sample; (ii) applying the test sample to a separation medium to effect separation of more than one constituent sample wherein a constituent of the separated sample comprises an antibody fragment of an antibody-drug conjugate compound having Formula I, or an antibody fragment or metabolite thereof, and in which p is 0, 1, 2, 3, 4, 5, 6, 7 or 8; and (iii) establish the mass or ratio between the mass and the charge and quantify one or more separate sample constituents that is an antibody fragment or an antibody-drug conjugate compound having Formula I or a metabolite thereof , where p is 0, 1, 2, 3, 4, 5, 6, 7 or 8, by mass spectrometry with single ion monitoring (SIM). |
| priorityDate | 2004-04-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 44.